Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Bertilsson

Showing results (81-90 of 263) with videos related to

Pageof 27
Sort By:
Clinical Pharmacology and Therapeutics|November 14, 1997
Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoinY Böttiger, G Tybring, E Götharson, et al.
Clinical Pharmacology and Therapeutics|August 1, 1997
Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjectsG Tybring, Y Böttiger, J Widén, et al.
Clinical Pharmacology and Therapeutics|January 1, 1987
Little anticholinergic effect of E-10-hydroxynortriptyline compared with nortriptyline in healthy subjectsC Nordin, L Bertilsson, K Otani, et al.
Pharmacogenetics|November 14, 1997
An S-mephenytoin cysteine conjugate identified in urine of extensive but not of poor metabolizers of S-mephenytoinG Tybring, J Nordin, T Bergman, et al.
Therapeutic Drug Monitoring|November 1, 1989
Diazepam treatment does not influence the debrisoquine or mephenytoin hydroxylation phenotyping testsE Spina, A L Buemi, E Sanz, et al.
Clinical Neuropharmacology|January 1, 1992
Genetic factors in the metabolism of haloperidolA Llerena, M L Dahl, B Ekqvist, et al.
Therapeutic Drug Monitoring|June 1, 1992
Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizersA Llerena, M L Dahl, B Ekqvist, et al.
Psychopharmacology Series|January 1, 1993
Disposition of the neuroleptics perphenazine, zuclopenthixol, and haloperidol cosegregates with polymorphic debrisoquine hydroxylationL Bertilsson, M L Dahl, B Ekqvist, et al.
Lancet (London, England)|February 16, 1985
Valpromide/carbamazepine and risk of teratogenicityG M Pacifici, T Tomson, L Bertilsson, et al.
Pharmacology & Toxicology|April 1, 1987
Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatmentK Brøsen, L F Gram, T Haghfelt, et al.
Pageof 27

Showing results (81-90 of 263) with videos related to

Sort By:
Pageof 27
Clinical Pharmacology and Therapeutics|November 14, 1997
Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoinY Böttiger, G Tybring, E Götharson, et al.
Clinical Pharmacology and Therapeutics|August 1, 1997
Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjectsG Tybring, Y Böttiger, J Widén, et al.
Clinical Pharmacology and Therapeutics|January 1, 1987
Little anticholinergic effect of E-10-hydroxynortriptyline compared with nortriptyline in healthy subjectsC Nordin, L Bertilsson, K Otani, et al.
Pharmacogenetics|November 14, 1997
An S-mephenytoin cysteine conjugate identified in urine of extensive but not of poor metabolizers of S-mephenytoinG Tybring, J Nordin, T Bergman, et al.
Therapeutic Drug Monitoring|November 1, 1989
Diazepam treatment does not influence the debrisoquine or mephenytoin hydroxylation phenotyping testsE Spina, A L Buemi, E Sanz, et al.
Clinical Neuropharmacology|January 1, 1992
Genetic factors in the metabolism of haloperidolA Llerena, M L Dahl, B Ekqvist, et al.
Therapeutic Drug Monitoring|June 1, 1992
Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizersA Llerena, M L Dahl, B Ekqvist, et al.
Psychopharmacology Series|January 1, 1993
Disposition of the neuroleptics perphenazine, zuclopenthixol, and haloperidol cosegregates with polymorphic debrisoquine hydroxylationL Bertilsson, M L Dahl, B Ekqvist, et al.
Lancet (London, England)|February 16, 1985
Valpromide/carbamazepine and risk of teratogenicityG M Pacifici, T Tomson, L Bertilsson, et al.
Pharmacology & Toxicology|April 1, 1987
Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatmentK Brøsen, L F Gram, T Haghfelt, et al.
Pageof 27